Legend Biotech Corp Current And Deferred Tax Relating To Items Charged Or Credited Directly To Equity
Legend Biotech Corp (LEGN) reported Current And Deferred Tax Relating To Items Charged Or Credited Directly To Equity of $14.20 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity · last filed 2026-03-10
| Period end | Current And Deferred Tax Relating To Items Charged Or Credited Directly To Equity 12 month | Current And Deferred Tax Relating To Items Charged Or Credited Directly To Equity 12 month as first filed |
|---|---|---|
| 2025-12-31 | $14.20M 20-F · filed 2026-03-10 | |
| 2024-12-31 | $18.90M 20-F · filed 2026-03-10 | $18.89M 20-F · filed 2025-03-11 |
| 2023-12-31 | -$1.90M 20-F · filed 2026-03-10 | -$1.86M 20-F · filed 2024-03-19 |
| 2022-12-31 | $625.00K 20-F · filed 2025-03-11 | |
| 2021-12-31 | -$3.61M 20-F · filed 2024-03-19 | $1.00K 20-F · filed 2022-03-31 |
| 2020-12-31 | -$41.91M 20-F · filed 2023-03-30 | -$4.14M 20-F · filed 2021-04-02 |
| 2019-12-31 | -$25.73M 20-F/A · filed 2023-02-17 | $2.60M 20-F · filed 2021-04-02 |
| 2018-12-31 | $1.17M 20-F · filed 2021-04-02 |